Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Exclusions
Mortality
ICU
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 remdesivir studies
00.250.50.7511.251.51.752+Wang (RCT)-9%1.09 [0.54-2.18]death22/15810/78Improvement, RR [CI]TreatmentControlOlender59%0.41 [0.24-0.71]death24/312102/818Spinner (RCT)35%0.65 [0.18-2.40]death5/3844/200Pasquini16%0.84 [0.69-0.94]death14/2524/26Fried61%0.39 [0.15-0.99]death4/482,510/11,673Beigel (RCT)27%0.73 [0.52-1.03]death541 (n)521 (n)SOLIDARITY (RCT)5%0.95 [0.81-1.11]death301/2,743303/2,708Solh47%0.53 [0.39-0.70]death63/219202/424Flisiak49%0.51 [0.19-1.30]death5/12217/211Garibaldi20%0.80 [0.46-1.41]death23/30345/303Ullah-100%2.00 [0.67-5.94]death8/304/30Goldberg9%0.91 [0.50-1.67]hosp. time29 (n)113 (n)Tsuzuki (PSM)9%0.91 [0.45-1.85]death9/7426/195Mahajan (RCT)-76%1.76 [0.46-6.82]death5/343/36Mulhem-86%1.86 [0.21-5.24]death1/8515/3,211Aghajani19%0.81 [0.46-1.46]death46 (n)945 (n)Arch (PSM)20%0.80 [0.64-0.98]death203/1,491777/4,676Barrat-Due (DB RCT)0%1.00 [0.20-4.60]death3/374/53Ohl (PSM)-6%1.06 [0.83-1.36]death143/1,172124/1,172Madan44%0.56 [0.33-0.95]death23/39827/260Kuno (PSM)1%0.99 [0.84-1.17]death214/999216/999Diaz35%0.65 [0.46-0.92]death33/286173/852Ader (RCT)6%0.94 [0.59-1.45]death34/41437/418Tau​2 = 0.04; I​2 = 56.6%Late treatment21%0.79 [0.70-0.90]1,137/9,8735,123/29,92221% improvementAll studies21%0.79 [0.70-0.90]1,137/9,8735,123/29,92221% improvement23 remdesivir COVID-19 studiesc19rmd.com Sep 26, 2021Tau​2 = 0.04; I​2 = 56.6%; Z = 3.57Effect extraction pre-specifiedFavors remdesivirFavors control 00.250.50.7511.251.51.752+Wang (RCT)-9%1.09 [0.54-2.18]death22/15810/78Improvement, RR [CI]TreatmentControlOlender59%0.41 [0.24-0.71]death24/312102/818Spinner (RCT)35%0.65 [0.18-2.40]death5/3844/200Pasquini16%0.84 [0.69-0.94]death14/2524/26Beigel (RCT)27%0.73 [0.52-1.03]death541 (n)521 (n)SOLIDARITY (RCT)5%0.95 [0.81-1.11]death301/2,743303/2,708Flisiak49%0.51 [0.19-1.30]death5/12217/211Garibaldi20%0.80 [0.46-1.41]death23/30345/303Ullah-100%2.00 [0.67-5.94]death8/304/30Goldberg9%0.91 [0.50-1.67]hosp. time29 (n)113 (n)Tsuzuki (PSM)9%0.91 [0.45-1.85]death9/7426/195Mahajan (RCT)-76%1.76 [0.46-6.82]death5/343/36Aghajani19%0.81 [0.46-1.46]death46 (n)945 (n)Arch (PSM)20%0.80 [0.64-0.98]death203/1,491777/4,676Barrat-Due (DB RCT)0%1.00 [0.20-4.60]death3/374/53Ohl (PSM)-6%1.06 [0.83-1.36]death143/1,172124/1,172Kuno (PSM)1%0.99 [0.84-1.17]death214/999216/999Diaz35%0.65 [0.46-0.92]death33/286173/852Ader (RCT)6%0.94 [0.59-1.45]death34/41437/418Tau​2 = 0.02; I​2 = 37.4%Late treatment15%0.85 [0.76-0.95]1,046/9,2001,869/14,35415% improvementAll studies15%0.85 [0.76-0.95]1,046/9,2001,869/14,35415% improvement19 remdesivir COVID-19 studies after exclusionsc19rmd.com Sep 26, 2021Tau​2 = 0.02; I​2 = 37.4%; Z = 2.86Effect extraction pre-specifiedFavors remdesivirFavors control 00.250.50.7511.251.51.752+Wang (RCT)-9%1.09 [0.54-2.18]22/15810/78Improvement, RR [CI]TreatmentControlOlender59%0.41 [0.24-0.71]24/312102/818Spinner (RCT)35%0.65 [0.18-2.40]5/3844/200Pasquini16%0.84 [0.69-0.94]14/2524/26Fried61%0.39 [0.15-0.99]4/482,510/11,673Beigel (RCT)27%0.73 [0.52-1.03]541 (n)521 (n)SOLIDARITY (RCT)5%0.95 [0.81-1.11]301/2,743303/2,708Solh47%0.53 [0.39-0.70]63/219202/424Flisiak49%0.51 [0.19-1.30]5/12217/211Garibaldi20%0.80 [0.46-1.41]23/30345/303Ullah-100%2.00 [0.67-5.94]8/304/30Tsuzuki (PSM)9%0.91 [0.45-1.85]9/7426/195Mahajan (RCT)-76%1.76 [0.46-6.82]5/343/36Mulhem-86%1.86 [0.21-5.24]1/8515/3,211Aghajani19%0.81 [0.46-1.46]46 (n)945 (n)Arch (PSM)20%0.80 [0.64-0.98]203/1,491777/4,676Barrat-Due (DB RCT)0%1.00 [0.20-4.60]3/374/53Ohl (PSM)-6%1.06 [0.83-1.36]143/1,172124/1,172Madan44%0.56 [0.33-0.95]23/39827/260Kuno (PSM)1%0.99 [0.84-1.17]214/999216/999Diaz35%0.65 [0.46-0.92]33/286173/852Ader (RCT)6%0.94 [0.59-1.45]34/41437/418Tau​2 = 0.04; I​2 = 58.5%Late treatment21%0.79 [0.69-0.90]1,137/9,8445,123/29,80921% improvementAll studies21%0.79 [0.69-0.90]1,137/9,8445,123/29,80921% improvement22 remdesivir COVID-19 mortality resultsc19rmd.com Sep 26, 2021Tau​2 = 0.04; I​2 = 58.5%; Z = 3.53Favors remdesivirFavors control 00.250.50.7511.251.51.752+Kuno (PSM)-17%1.17 [1.00-1.37]260/999222/999Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-17%1.17 [1.00-1.37]260/999222/999-17% improvementAll studies-17%1.17 [1.00-1.37]260/999222/999-17% improvement1 remdesivir COVID-19 ICU resultc19rmd.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.98Favors remdesivirFavors control 00.250.50.7511.251.51.752+Goldberg9%0.91 [0.50-1.67]hosp. time29 (n)113 (n)Improvement, RR [CI]TreatmentControlTsuzuki (PSM)-27%1.27 [1.10-1.47]hosp. time74 (n)195 (n)Ohl (PSM)-100%2.00 [1.33-3.02]hosp. time1,172 (n)1,172 (n)Tau​2 = 0.06; I​2 = 64.4%Late treatment-36%1.36 [0.96-1.94]0/1,2750/1,480-36% improvementAll studies-36%1.36 [0.96-1.94]0/1,2750/1,480-36% improvement3 remdesivir COVID-19 hospitalization resultsc19rmd.com Sep 26, 2021Tau​2 = 0.06; I​2 = 64.4%; Z = 1.72Favors remdesivirFavors control 00.250.50.7511.251.51.752+Wang (RCT)-9%1.09 [0.54-2.18]death22/15810/78Improvement, RR [CI]TreatmentControlOlender59%0.41 [0.24-0.71]death24/312102/818Spinner (RCT)35%0.65 [0.18-2.40]death5/3844/200Pasquini16%0.84 [0.69-0.94]death14/2524/26Fried61%0.39 [0.15-0.99]death4/482,510/11,673Beigel (RCT)27%0.73 [0.52-1.03]death541 (n)521 (n)SOLIDARITY (RCT)5%0.95 [0.81-1.11]death301/2,743303/2,708Solh47%0.53 [0.39-0.70]death63/219202/424Flisiak49%0.51 [0.19-1.30]death5/12217/211Garibaldi20%0.80 [0.46-1.41]death23/30345/303Ullah-100%2.00 [0.67-5.94]death8/304/30Tsuzuki (PSM)9%0.91 [0.45-1.85]death9/7426/195Mahajan (RCT)-76%1.76 [0.46-6.82]death5/343/36Mulhem-86%1.86 [0.21-5.24]death1/8515/3,211Aghajani19%0.81 [0.46-1.46]death46 (n)945 (n)Arch (PSM)20%0.80 [0.64-0.98]death203/1,491777/4,676Barrat-Due (DB RCT)0%1.00 [0.20-4.60]death3/374/53Ohl (PSM)-6%1.06 [0.83-1.36]death143/1,172124/1,172Madan44%0.56 [0.33-0.95]death23/39827/260Kuno (PSM)1%0.99 [0.84-1.17]death214/999216/999Diaz35%0.65 [0.46-0.92]death33/286173/852Ader (RCT)6%0.94 [0.59-1.45]death34/41437/418Tau​2 = 0.04; I​2 = 58.5%Late treatment21%0.79 [0.69-0.90]1,137/9,8445,123/29,80921% improvementAll studies21%0.79 [0.69-0.90]1,137/9,8445,123/29,80921% improvement22 remdesivir COVID-19 serious outcomesc19rmd.com Sep 26, 2021Tau​2 = 0.04; I​2 = 58.5%; Z = 3.53Effect extraction pre-specifiedFavors remdesivirFavors control 00.250.50.7511.251.51.752+Goldberg0%1.00 [0.92-1.09]viral+29 (n)113 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment0%1.00 [0.92-1.09]0/290/1130% improvementAll studies0%1.00 [0.92-1.09]0/290/1130% improvement1 remdesivir COVID-19 viral clearance resultc19rmd.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.03Favors remdesivirFavors control 00.250.50.7511.251.51.752+Wang (RCT)-9%1.09 [0.54-2.18]death22/15810/78Improvement, RR [CI]TreatmentControlSpinner (RCT)35%0.65 [0.18-2.40]death5/3844/200Beigel (RCT)27%0.73 [0.52-1.03]death541 (n)521 (n)SOLIDARITY (RCT)5%0.95 [0.81-1.11]death301/2,743303/2,708Mahajan (RCT)-76%1.76 [0.46-6.82]death5/343/36Barrat-Due (DB RCT)0%1.00 [0.20-4.60]death3/374/53Ader (RCT)6%0.94 [0.59-1.45]death34/41437/418Tau​2 = 0.00; I​2 = 0.0%Late treatment8%0.92 [0.81-1.05]370/4,311361/4,0148% improvementAll studies8%0.92 [0.81-1.05]370/4,311361/4,0148% improvement7 remdesivir COVID-19 Randomized Controlled Trialsc19rmd.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.27Effect extraction pre-specifiedFavors remdesivirFavors control 00.250.50.7511.251.51.752+Wang (RCT)-9%1.09 [0.54-2.18]22/15810/78Improvement, RR [CI]TreatmentControlSpinner (RCT)35%0.65 [0.18-2.40]5/3844/200Beigel (RCT)27%0.73 [0.52-1.03]541 (n)521 (n)SOLIDARITY (RCT)5%0.95 [0.81-1.11]301/2,743303/2,708Mahajan (RCT)-76%1.76 [0.46-6.82]5/343/36Barrat-Due (DB RCT)0%1.00 [0.20-4.60]3/374/53Ader (RCT)6%0.94 [0.59-1.45]34/41437/418Tau​2 = 0.00; I​2 = 0.0%Late treatment8%0.92 [0.81-1.05]370/4,311361/4,0148% improvementAll studies8%0.92 [0.81-1.05]370/4,311361/4,0148% improvement7 remdesivir COVID-19 RCT mortality resultsc19rmd.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.27Favors remdesivirFavors control 00.250.50.7511.251.51.752+Wang (RCT)-9%1.09 [0.54-2.18]death22/15810/78Improvement, RR [CI]TreatmentControlOlender59%0.41 [0.24-0.71]death24/312102/818Spinner (RCT)35%0.65 [0.18-2.40]death5/3844/200Pasquini16%0.84 [0.69-0.94]death14/2524/26Fried61%0.39 [0.15-0.99]death4/482,510/11,673Beigel (RCT)27%0.73 [0.52-1.03]death541 (n)521 (n)SOLIDARITY (RCT)5%0.95 [0.81-1.11]death301/2,743303/2,708Ullah-100%2.00 [0.67-5.94]death8/304/30Goldberg9%0.91 [0.50-1.67]hosp. time29 (n)113 (n)Mahajan (RCT)-76%1.76 [0.46-6.82]death5/343/36Mulhem-86%1.86 [0.21-5.24]death1/8515/3,211Aghajani19%0.81 [0.46-1.46]death46 (n)945 (n)Barrat-Due (DB RCT)0%1.00 [0.20-4.60]death3/374/53Ohl (PSM)-6%1.06 [0.83-1.36]death143/1,172124/1,172Kuno (PSM)1%0.99 [0.84-1.17]death214/999216/999Diaz35%0.65 [0.46-0.92]death33/286173/852Ader (RCT)6%0.94 [0.59-1.45]death34/41437/418Tau​2 = 0.03; I​2 = 44.9%Late treatment15%0.85 [0.74-0.98]811/7,2664,029/23,85315% improvementAll studies15%0.85 [0.74-0.98]811/7,2664,029/23,85315% improvement17 remdesivir COVID-19 peer reviewed trialsc19rmd.com Sep 26, 2021Tau​2 = 0.03; I​2 = 44.9%; Z = 2.23Effect extraction pre-specifiedFavors remdesivirFavors control 00.250.50.7511.251.51.752+Wang (RCT)-9%1.09 [0.54-2.18]death22/15810/78Improvement, RR [CI]TreatmentControlWang (RCT)24%0.76 [0.29-1.95]death8/717/47Wang (RCT)-48%1.48 [0.45-4.88]death12/843/31Olender59%0.41 [0.24-0.71]death24/312102/818Spinner (RCT)35%0.65 [0.18-2.40]death5/3844/200Pasquini16%0.84 [0.69-0.94]death14/2524/26Fried61%0.39 [0.15-0.99]death4/482,510/11,673Fried-37%1.37 [0.81-2.30]ventilation11/481,956/11,673Beigel (RCT)27%0.73 [0.52-1.03]death541 (n)521 (n)SOLIDARITY (RCT)5%0.95 [0.81-1.11]death301/2,743303/2,708Solh47%0.53 [0.39-0.70]death63/219202/424Flisiak49%0.51 [0.19-1.30]death5/12217/211Flisiak58%0.42 [0.13-1.18]death4/8214/119Flisiak56%0.44 [0.21-0.86]no improv.9/12236/211Garibaldi20%0.80 [0.46-1.41]death23/30345/303Garibaldi35%0.65 [0.53-0.78]no improv.52/30380/303Ullah-100%2.00 [0.67-5.94]death8/304/30Ullah-250%3.50 [0.79-15.5]ventilation7/302/30Goldberg9%0.91 [0.50-1.67]hosp. time29 (n)113 (n)Goldberg0%1.00 [0.92-1.09]viral+29 (n)113 (n)Tsuzuki (PSM)9%0.91 [0.45-1.85]death9/7426/195Tsuzuki (PSM)-17%1.17 [0.37-3.69]ventilation4/749/195Tsuzuki (PSM)-27%1.27 [1.10-1.47]hosp. time74 (n)195 (n)Mahajan (RCT)-76%1.76 [0.46-6.82]death5/343/36Mahajan (RCT)-112%2.12 [0.41-10.8]ventilation4/342/36Mulhem-86%1.86 [0.21-5.24]death1/8515/3,211Aghajani19%0.81 [0.46-1.46]death46 (n)945 (n)Arch (PSM)20%0.80 [0.64-0.98]death203/1,491777/4,676Arch (PSM)18%0.82 [0.63-1.06]death140/1,502565/4,728Arch (PSM)-68%1.68 [1.19-2.34]ventilation106/1,498153/4,602Barrat-Due (DB RCT)0%1.00 [0.20-4.60]death3/374/53Ohl (PSM)-6%1.06 [0.83-1.36]death143/1,172124/1,172Ohl (PSM)-100%2.00 [1.33-3.02]hosp. time1,172 (n)1,172 (n)Madan44%0.56 [0.33-0.95]death23/39827/260Madan66%0.34 [0.12-0.96]death4/11227/260Madan62%0.38 [0.18-0.80]death9/22627/260Madan-60%1.60 [0.82-3.13]death10/6027/260Kuno (PSM)1%0.99 [0.84-1.17]death214/999216/999Kuno (PSM)0%1.00 [0.80-1.24]ventilation140/999140/999Kuno (PSM)-17%1.17 [1.00-1.37]ICU260/999222/999Diaz35%0.65 [0.46-0.92]death33/286173/852Ader (RCT)6%0.94 [0.59-1.45]death34/41437/418Ader (RCT)10%0.90 [0.70-1.15]7-point status414 (n)418 (n)Ader (RCT)-2%1.02 [0.80-1.30]7-point status414 (n)418 (n)remdesivir COVID-19 outcomesc19rmd.com Sep 26, 2021Favors remdesivirFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit